References
- Symmons D. P. Looking back: rheumatoid arthritis – aetiology, occurrence and mortality. Rheumatology (Oxford) 2005; 44(Suppl 4)iv14–17
- Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
- Aletaha D., Breedveld F. C., Smolen J. S. The need for new classification criteria for rheumatoid arthritis. Arthritis Rheum 2005; 52: 3333–6
- Rantapaa‐Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005; 34: 83–96
- Bridges S. L. Update on autoantibodies in rheumatoid arthritis. Curr Rheumatol Rep 2004; 6: 343–50
- Schellekens G. A., de Jong B. A., van den Hoogen F. H., van de Putte L. B., van Venrooij W. J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis‐specific autoantibodies. J Clin Invest 1998; 101: 273–81
- Schellekens G. A., Visser H., de Jong B. A., van den Hoogen F. H., Hazes J. M., Breedveld F. C., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155–63
- Bas S., Genevay S., Meyer O., Gabay C. Anti‐cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 677–80
- Vallbracht I., Rieber J., Oppermann M., Forger F., Siebert U., Helmke K. Diagnostic and clinical value of anti‐cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1079–84
- Bizzaro N., Mazzanti G., Tonutti E., Villalta D., Tozzoli R. Diagnostic accuracy of the anti‐citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089–93
- Soderlin M. K., Kastbom A., Kautiainen H., Leirisalo‐Repo M., Strandberg G., Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol 2004; 33: 185–8
- Recklies A. D., Baillargeon L., White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998; 41: 997–1006
- Vossenaar E. R., Smeets T. J., Kraan M. C., Raats J. M., van Venrooij W. J., Tak P. P. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004; 50: 3485–94
- Nielen M. M. J., van der Horst A. R., van Schaardenburg D., Horst‐Bruinsma I. E., van de Stadt R. J., Aarden L., et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005; 64: 1199–204
- Kwok J. S., Hui K. H., Lee T. L., Wong W., Lau Y. L., Wong R. W., et al. Anti‐cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005; 34: 359–66